Company news
Outlook Therapeutics, Inc. news in 2023
Outlook Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU
December 21, 2023
Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010
December 18, 2023
Outlook Therapeutics® Announces Strategic Organizational Realignment
December 5, 2023
Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path Forward for ONS-5010
November 26, 2023
Outlook Therapeutics® Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior VP - Head of Europe
November 13, 2023
Outlook Therapeutics® Provides Update on Type A Meetings with FDA
November 1, 2023
Outlook Therapeutics® to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology (INI) Conference
October 31, 2023
Outlook Therapeutics® Requests Type A Meeting With FDA
September 28, 2023
Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
September 20, 2023
Outlook Therapeutics® to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 4, 2023
Outlook Therapeutics® Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
August 29, 2023
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term Milestones
August 13, 2023
Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2023
July 31, 2023
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2023 and Provides Corporate Update
May 14, 2023
Outlook Therapeutics® to Present at the H.C. Wainwright BioConnect Investor Conference
April 26, 2023
Outlook Therapeutics® Confirms It Has No Exposure to Silicon Valley Bank
March 12, 2023
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2023 and Provides Corporate Update
February 13, 2023
Outlook Therapeutics® to Present at the SVB Securities Global Biopharma Conference
February 6, 2023
Outlook Therapeutics® Strengthens Medical Affairs and Commercial Expertise with Appointments of Surendra Sharma, MD, Senior Vice President of Medical Affairs and Glen Olsheim, Executive Director of Commercial Excellence
January 18, 2023